SWOG 0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastasis Starting Zoledronic Acid Treatment
June 10, 2009
Cancer - Side Effect Management
Principal Investigator: Robert A Chapman, MD
The purpose of this research study is to learn how often Osteonecrosis of the Jaw (ONJ) occurs in patients who are being treated with zoledronic acid during a 3 year time period after starting treatment. This study will also identify risk factors associated with ONJ.
Participant must have bone metastasis from multiple myeloma, solid tumors, or other malignancy for which intravenous bisphosphonate has clinical indications in the treatment of metastatic bone disease; All participants must be planning to receive zoledronic acid (as their sole bisphosphonate therapy) within 30 days after registration. (NOTE: Bisphosphonate therapy will continue thereafter as clinically indicated.); Participants must not have a pre-existing diagnosis of ONJ; Participants must not have a history of radiation to the maxillofacial area administered for therapeutic intent in the treatment of cancer.